Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) released its recent financial results announcement on Friday.
Amneal Pharmaceuticals announced its fourth-quarter revenue of $814.32 million, an 11% increase year over year, beating the consensus of $807.89 million.
The generic drug maker reported adjusted earnings of 21 cents, beating the Wall Street estimate of 18 cents.
In the fourth quarter, adjusted EBITDA reached $175 million, reflecting a 13% increase year-over-year.
The company highlighted the strong uptake of its specialty products, particularly CREXONT, while also noting a robust cadence of new product approvals in its Affordable Medicines segment.
Guidance
Amneal Pharmaceuticals expects fiscal 2026 adjusted earnings between 93 cents and $1.03, compared to the